AMY BAREMORE: Open Payments
NPI 1578193637 · JOPLIN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,167 in 73 payments from 13 companies in 2025. Trend: 2023 $2,144 · 2024 $1,743 · 2025 $2,167
Food & beverage: $2,167
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $413 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $247 |
| Otsuka America Pharmaceutical, Inc. | 6 | $233 |
| Vanda Pharmaceuticals Inc. | 11 | $230 |
| Axsome Therapeutics, Inc. | 9 | $216 |
| Supernus Pharmaceuticals, Inc. | 3 | $148 |
| E.R. Squibb & Sons, L.L.C. | 2 | $138 |
| Alkermes, Inc. | 1 | $129 |
| Neurocrine BioSciences, Inc. | 1 | $124 |
| Teva Pharmaceuticals USA, Inc. | 1 | $123 |
Products named: VRAYLAR, REXULTI, CAPLYTA, Auvelity, FANAPT, Qelbree, COBENFY, LYBALVI.
Industry payments across MO — which companies pay providers there.
